Home
    Disclaimer
    ← Back to bk-2C-B
    bk-2C-B molecular structure

    bk-2C-B Stats & Data

    Psychedelic Research-chemical
    bk-2cb bk-2-cb b-k-2cb b-k2cb b-k2-cb b-k2-c-b b-k-2-c-b bk2cb
    NPS DataHub
    MW310.57
    FormulaC10H13BrClNO3
    CAS2303508-66-7
    IUPACbeta-keto-2C-B
    SMILES[Cl-].NCC(=O)c1cc(OC)c(Br)cc1OC.[H+]
    InChIKeyQEGWLXAUBMCGTL-UHFFFAOYSA-N
    Phenethylamines; Cathinones; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic

    History & Culture

    bk-2C-B was first characterized in the scientific literature in 2004 by pharmacologist Richard Glennon and his research team, who synthesized and studied the compound as part of investigations into phenethylamine structure-activity relationships. The substance remained largely obscure until 2013, when it emerged on European designer drug markets as a novel psychoactive substance. Following its market appearance, bk-2C-B maintained a consistent presence without generating significant enthusiasm or notoriety within the research chemical community. Despite this relatively muted reception, the compound was sampled by a substantial number of users over subsequent years. It was typically distributed in both pressed pill and powder forms. Its availability persisted in the gray market until regulatory measures were implemented across several countries beginning in 2016.

    Effect Profile

    Curated + 31 Reports
    Psychedelic 6.5

    Strong visuals, auditory effects, and body load with mild headspace

    Visual Intensity×3
    1010
    Headspace Depth×3
    47.0
    Auditory Effects×1
    1010
    Body Load / Somatic Effects×1
    109.5
    Catalog Erowid
    Based on reports from:
    Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki bk-2C-B The Drug Users Bible bk-2C-B

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Experience Report Analysis

    Erowid
    31 Reports
    2012–2018 Date Range
    30 With Age Data
    26 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 31 experience reports (31 Erowid)

    31 Reports
    26 Effects Detected
    10 Positive
    8 Adverse
    8 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 10

    Euphoria 61.3% 70%
    Music Enhancement 54.8% 70%
    Color Enhancement 48.4% 70%
    Empathy 48.4% 70%
    Body High 48.4% 70%
    Stimulation 48.4% 70%
    Focus Enhancement 35.5% 70%
    Introspection 19.4% 70%
    Tactile Enhancement 19.4% 70%
    Creativity Enhancement 9.7% 70%

    Adverse Effects 8

    Anxiety 51.6% 70%
    Pupil Dilation 41.9% 70%
    Confusion 38.7% 70%
    Nausea 29.0% 70%
    Sweating 19.4% 70%
    Jaw Clenching 12.9% 70%
    Headache 9.7% 70%
    Increased Heart Rate 9.7% 70%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Heavy (n=12)
    Visual Distortions 100.0%
    Color Enhancement 83.3%
    Anxiety 66.7%
    Euphoria 66.7%
    Empathy 58.3%
    Nausea 58.3%
    Body High 58.3%
    Confusion 50.0%
    Music Enhancement 50.0%
    Closed-Eye Visuals 41.7%
    Open-Eye Visuals 41.7%
    Stimulation 41.7%
    Auditory Effects 41.7%
    Pupil Dilation 41.7%
    Focus Enhancement 33.3%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 31 experience reports.

    Limited tier coverage — most reports fall within the Heavy range. Effects at other dose levels may not be represented.

    Oral dose range: 100.0–200.0 mg (median 150.0 mg)
    Effect Heavy (n=12)
    visual distortions
    100%
    color enhancement
    83%
    anxiety
    67%
    euphoria
    67%
    empathy
    58%
    nausea
    58%
    body high
    58%
    confusion
    50%
    music enhancement
    50%
    closed-eye visuals
    42%
    open-eye visuals
    42%
    stimulation
    42%
    auditory effects
    42%
    pupil dilation
    42%
    focus enhancement
    33%
    hospital
    33%
    introspection
    25%
    tactile enhancement
    25%
    sedation
    25%
    sweating
    25%

    Showing top 20 of 28 effects

    Dosage Distribution

    Dose distribution from experience reports

    Median: 150.0 mg IQR: 100.0–200.0 mg n=23

    Real-World Dose Distribution

    62K Doses

    From 60 individual dose entries

    Oral (n=51)

    Median: 100.0mg 25th: 57.5mg 75th: 150.0mg 90th: 250.0mg
    mg/kg median: 1.413 mg/kg 75th: 2.381

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 2.297 mg/kg IQR: 1.471–2.696 mg/kg n=22

    Redose Patterns

    Redosing behavior across 26 reports

    38.5% Redosed
    1.7 Avg Doses
    120m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Canada Controlled substance Became a controlled substance in October 2016. Possession, production, and distribution are prohibited under Canadian drug scheduling.
    Germany Controlled substance Classified as an illegal controlled substance. Manufacturing, possession, and distribution are prohibited without authorization.
    Switzerland Controlled substance Listed as a controlled substance under Swiss narcotics legislation. Unauthorized possession and distribution are prohibited.
    United Kingdom Controlled (Psychoactive Substances Act 2016) Prohibited under the Psychoactive Substances Act 2016, which broadly bans the production, supply, and importation of psychoactive substances intended for human consumption. Personal possession is not criminalized under this act, but supply-related offenses carry penalties of up to 7 years imprisonment.
    ← Back to bk-2C-B